Replies to post #36983 on Biotech Values

[DewDiligence]

> ANDS may not meet their objective in this new study.<

The current CEO won’t be around to find out—how convenient. If ANA975 does make it back to the clinic, it will be in 2H07 at the earliest. It’s pretty hard to see how this compound will be a factor in the HCV arena.